On Dec. 1, Pfizer (NYSE: PFE) reported some less-than-great news to investors. In short, its latest attempt at developing a drug to compete with Novo Nordisk's blockbuster medicine Ozempic will not be advancing into late-stage clinical trials. Now, the company's bid to capture portions of the extremely lucrative type 2 diabetes and obesity drug markets looks like it's in trouble.
In this article, we discuss 10 cheap dividend stocks with high yields. You can skip our detailed analysis of dividend stocks and their performance in the past, and go directly to read 5 Cheap Dividend Stocks with High Yields. In 2022, value stocks did better than growth stocks, marking the first time of value outperformance […]
AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.